Literature DB >> 15604250

Enhancer-dependent splicing of FGFR1 alpha-exon is repressed by RNA interference-mediated down-regulation of SRp55.

Wei Jin1, Gilbert J Cote.   

Abstract

The FGFR1 gene transcript is alternatively processed to produce functionally different receptor forms. Previously, we identified a 69-nucleotide exonic splicing enhancer (ESE) required for alpha-exon inclusion in JEG3 cells. In the present study, we found that this sequence is composed of three independent elements, two smaller ESE sequences flanking an exonic splicing silencer sequence. Ultraviolet cross-linking and immunoprecipitation identified ESE-specific binding of the splicing regulator SRp55. A RNA interference-mediated decrease in SRp55 confirmed the significance of this interaction. There was a 6- to 14-fold decrease in exon inclusion on ablation of SRp55. In SNB19 glioblastoma cells, which normally skip this exon, SRp55 was also demonstrated to play a role in exon inclusion after the removal of intronic splicing silencer sequences. These observations indicate that SRp55 plays a major role in maintaining normal FGFR1 alpha-exon inclusion, which is subject to dominant intronic splicing silencer-mediated and exonic splicing silencer-mediated inhibition in SNB19 cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15604250     DOI: 10.1158/0008-5472.CAN-04-0716

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  The RNAissance family: SR proteins as multifaceted regulators of gene expression.

Authors:  Jonathan M Howard; Jeremy R Sanford
Journal:  Wiley Interdiscip Rev RNA       Date:  2014-08-22       Impact factor: 9.957

2.  TDP-43 overexpression enhances exon 7 inclusion during the survival of motor neuron pre-mRNA splicing.

Authors:  Jayarama Krishnan Bose; I-Fan Wang; Li Hung; Woan-Yuh Tarn; C-K James Shen
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

3.  Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines.

Authors:  Naoki Ueda; Hidenori Shiraha; Tatsuya Fujikawa; Nobuyuki Takaoka; Yutaka Nakanishi; Mayumi Suzuki; Noriyuki Matsuo; Shigetomi Tanaka; Shin-Ichi Nishina; Masayuki Uemura; Akinobu Takaki; Yasushi Shiratori; Kazuhide Yamamoto
Journal:  Mol Oncol       Date:  2008-06-20       Impact factor: 6.603

4.  Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas.

Authors:  Clare V Lefave; Massimo Squatrito; Sandra Vorlova; Gina L Rocco; Cameron W Brennan; Eric C Holland; Ying-Xian Pan; Luca Cartegni
Journal:  EMBO J       Date:  2011-09-13       Impact factor: 11.598

5.  SRSF6 Regulates the Alternative Splicing of the Apoptotic Fas Gene by Targeting a Novel RNA Sequence.

Authors:  Namjeong Choi; Ha Na Jang; Jagyeong Oh; Jiyeon Ha; Hyungbin Park; Xuexiu Zheng; Sunjae Lee; Haihong Shen
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

6.  FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells.

Authors:  Ming Zhao; Ming-Lei Zhuo; Xiaofeng Zheng; Xiaoping Su; Funda Meric-Bernstam
Journal:  Oncotarget       Date:  2019-01-01

Review 7.  Alternative Splicing in Angiogenesis.

Authors:  Elizabeth Bowler; Sebastian Oltean
Journal:  Int J Mol Sci       Date:  2019-04-26       Impact factor: 5.923

8.  Alternative splicing and tumor progression.

Authors:  Claudia Ghigna; Cristina Valacca; Giuseppe Biamonti
Journal:  Curr Genomics       Date:  2008-12       Impact factor: 2.236

Review 9.  VEGF-A splicing: the key to anti-angiogenic therapeutics?

Authors:  Steven J Harper; David O Bates
Journal:  Nat Rev Cancer       Date:  2008-10-16       Impact factor: 60.716

10.  Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.

Authors:  Dawid G Nowak; Jeanette Woolard; Elianna Mohamed Amin; Olga Konopatskaya; Moin A Saleem; Amanda J Churchill; Michael R Ladomery; Steven J Harper; David O Bates
Journal:  J Cell Sci       Date:  2008-10-15       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.